SoftOx Solutions

Equities

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.218 ^NOK	0.00%		-0.91%	-93.27%

Apr. 18	Transcript : SoftOx Solutions AS - Special Call
Mar. 20	SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI

SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023

June 21, 2023 at 10:15 am EDT

SoftOx Solutions AS reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was NOK 9.67 million compared to NOK 1.05 million a year ago. Net loss was NOK 2.41 million compared to NOK 24 million a year ago.

Latest news about SoftOx Solutions

Transcript : SoftOx Solutions AS - Special Call	Apr. 18
SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 19	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	Jan. 16	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	Jan. 10	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Oct. 31	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-09-26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	23-09-18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	23-06-08	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	23-06-02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	23-03-27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	23-03-24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	23-01-09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	22-12-20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	22-12-19	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	22-12-19	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-12-14	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	22-10-19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	22-10-18	CI
SoftOx Solutions Signs $2 Million Convertible Loan Deal, Secures Refinancing	22-10-11	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding from Aubert Invest AS, Pro AS, Almhaug Bolig AS and other investors	22-10-10	CI
SoftOx Solutions AS Announces Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	22-10-03	CI

Chart SoftOx Solutions

Duration

Period

More charts

Company Profile

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

2024-09-03 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-93.27%	9.94M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs